Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications
Frontiers in Immunology · 2025
DOI: 10.3389/fimmu.2025.1633338 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Dan Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Glioma, Epigenesis, Genetic, Tumor Escape, Immune Evasion. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gliomas are the most common primary malignant tumors of the central nervous system (CNS), and despite progress in molecular diagnostics and targeted therapies, their prognosis remains poor. In recent years, immunotherapy has emerged as a promising treatment modality in cancer therapy. However, the inevitable immune evasion by tumor cells is a key barrier affecting therapeutic efficacy. Epigenetic regulation, such as DNA methylation, histone modification, and non-coding RNA expression, plays a crucial role in the occurrence, development, and immune evasion of gliomas. These modifications can dynamically regulate gene expression, leading to the silencing of tumor-associated antigens, dysregulation of pro-inflammatory cytokines, and dynamic modulation of immune checkpoints (such as PD-L1). This review systematically elucidates the key mechanisms by which epigenetic regulation promotes immune evasion in gliomas and details three interconnected mechanisms: 1) epigenetic silencing of tumor-associated antigens and antigen-presenting machinery; 2) dysregulation of pro-inflammatory cytokine secretion; and 3) dynamic modulation of PD-L1 expression through chromatin remodeling. We emphasize the potential of combining epigenetic therapies with immunotherapies to enhance anti-tumor immune responses and overcome treatment resistance in gliomas. Future research should focus on developing biomarker-driven epigenetic immunotherapies and exploring the complex interplay between epigenetic modifications, glioma cells, and the tumor immune microenvironment to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
- Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Zitieren
APA
Wu, D., Ju, D., Zhao, Y., Liu, W., Liu, Q., & Liang, Y. (2025). Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1633338
Vancouver
Wu D, Ju D, Zhao Y, Liu W, Liu Q, Liang Y. Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1633338
BibTeX
@article{Wu2025,
author = {Wu, Dan and Ju, Dongen and Zhao, Yujia and Liu, Wenna and Liu, Qingqing and Liang, Ying},
title = {Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications},
journal = {Frontiers in Immunology},
year = {2025},
doi = {10.3389/fimmu.2025.1633338}
}
EUVIMED